Movers and SHAKERS
PDS Biotechnology (PDSB)
Well Funded to Advance Cancer Programs
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
PDS Biotechnology F2019 Financial Results, Boosting Cash Position. After the close on Friday March 27, PDS Biotechnology announced financial results for F2019. The company reported a net loss of $6.9 mm compared to our estimate of $7.5 mm as our forecast included higher R&D and SG&A expenses. As of December 31, 2019, PDS reported cash and cash equivalents of $12.2 mm. In February, the company raised an additional $11.9 mm. We believe strengthened cash position allows management to advance its cancer clinical programs.
Business update highlights importance of Phase I results. PDS Biotechnology completed a Phase I clinical trial on the use of its lead drug PDS0101 for the treatment of cervical intraepithelial neoplasia (CIN). In the trial, the treatment elicited a potent anti-cancer immune response. 60% of treated patients showed regression of lesions. This year, the company plans to initiate several Phase II clinical trials evaluating PDS0101 for the treatment of...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.